Emir Hadzijusufovic

Vienna, Austria

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 58 publications

Subtype-specific outcome after allogeneic hematopoietic cell transplantation in advanced systemic mastocytosis: a registry study of the European competence network on mastocytosis.

Subtype-specific outcome after allogeneic hematopoietic cell transplantation in advanced systemic mastocytosis: a registry study of the European competence network on mastocytosis.

Journal: Experimental hematology & oncology
Published: June 21, 2026

CDK6 inactivation counteracts CALR-mutant-induced MPN evolution and sensitizes MPN stem cells to interferon-α treatment.

CDK6 inactivation counteracts CALR-mutant-induced MPN evolution and sensitizes MPN stem cells to interferon-α treatment.

Journal: HemaSphere
Published: July 31, 2025

ADH5/ALDH2 dehydrogenases and DNA polymerase theta protect normal and malignant hematopoietic cells from formaldehyde challenge: therapeutic implications.

ADH5/ALDH2 dehydrogenases and DNA polymerase theta protect normal and malignant hematopoietic cells from formaldehyde challenge: therapeutic implications.

Journal: Leukemia
Published: January 20, 2025

Polθ activity modulates sensitivity to standard therapies in DNMT3A-deficient leukemia.

Polθ activity modulates sensitivity to standard therapies in DNMT3A-deficient leukemia.

Journal: Cell reports. Medicine
Published: October 22, 2024

DNA polymerase theta-mediated DNA repair is a functional dependency and therapeutic vulnerability in DNMT3A deficient leukemia cells.

DNA polymerase theta-mediated DNA repair is a functional dependency and therapeutic vulnerability in DNMT3A deficient leukemia cells.

Journal: bioRxiv : the preprint server for biology
Published: October 16, 2024

Serum chemistry profiling and prognostication in systemic mastocytosis: a registry-based study of the ECNM and GREM.

Serum chemistry profiling and prognostication in systemic mastocytosis: a registry-based study of the ECNM and GREM.

Journal: Blood advances
Published: January 24, 2024

Dual specific STAT3/5 degraders effectively block acute myeloid leukemia and natural killer/T cell lymphoma.

Dual specific STAT3/5 degraders effectively block acute myeloid leukemia and natural killer/T cell lymphoma.

Journal: HemaSphere
Published: December 06, 2023

Clonal medicine targeting DNA damage response eradicates leukemia.

Clonal medicine targeting DNA damage response eradicates leukemia.

Journal: Leukemia
Published: October 09, 2023

Prevalence of hypersensitivity reactions in various forms of mastocytosis: A pilot study of 2485 adult patients with mastocytosis collected in the ECNM registry.

Prevalence of hypersensitivity reactions in various forms of mastocytosis: A pilot study of 2485 adult patients with mastocytosis collected in the ECNM registry.

Journal: Allergy
Published: October 07, 2023

Vienna Cancer Stem Cell Club (VCSCC): 20 year jubilee and future perspectives.

Vienna Cancer Stem Cell Club (VCSCC): 20 year jubilee and future perspectives.

Journal: Expert review of hematology
Published: July 26, 2023

Engraftment in NSGSCF mice correlates with the WHO category and prognosis in systemic mastocytosis.

Engraftment in NSGSCF mice correlates with the WHO category and prognosis in systemic mastocytosis.

Journal: Leukemia
Published: December 30, 2022

Phenotypic characterization of disease-initiating stem cells in JAK2- or CALR-mutated myeloproliferative neoplasms.

Phenotypic characterization of disease-initiating stem cells in JAK2- or CALR-mutated myeloproliferative neoplasms.

Journal: American journal of hematology
Published: November 30, 2022
Showing 1-12 of 58

Last Updated: 09/26/2026